Literature DB >> 20959469

Tumorigenic and metastatic activity of human thyroid cancer stem cells.

Matilde Todaro1, Flora Iovino, Vincenzo Eterno, Patrizia Cammareri, Guido Gambara, Virginia Espina, Gaspare Gulotta, Francesco Dieli, Silvia Giordano, Ruggero De Maria, Giorgio Stassi.   

Abstract

Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDH(high)) activity and unlimited replication potential. ALDH(high) cells can be expanded indefinitely in vitro as tumor spheres, which retain the tumorigenic potential upon delivery in immunocompromised mice. Orthotopic injection of minute numbers of thyroid cancer stem cells recapitulates the behavior of the parental tumor, including the aggressive metastatic features of undifferentiated thyroid carcinomas, which are sustained by constitutive activation of cMet and Akt in thyroid cancer stem cells. The identification of tumorigenic and metastagenic thyroid cancer cells may provide unprecedented preclinical tools for development and preclinical validation of novel targeted therapies. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20959469     DOI: 10.1158/0008-5472.CAN-10-1994

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  96 in total

Review 1.  Regulation of stem cell plasticity: mechanisms and relevance to tissue biology and cancer.

Authors:  Robert Strauss; Petra Hamerlik; André Lieber; Jiri Bartek
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

2.  Bioluminescent human thyrospheres allow noninvasive detection of anaplastic thyroid cancer growth and metastases in vivo.

Authors:  Ashley N Reeb; Wen Li; Reigh-Yi Lin
Journal:  Thyroid       Date:  2014-05-20       Impact factor: 6.568

3.  The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.

Authors:  Dang Vu-Phan; Vladimir Grachtchouk; Jingcheng Yu; Lesley A Colby; Max S Wicha; Ronald J Koenig
Journal:  Endocr Relat Cancer       Date:  2013-09-11       Impact factor: 5.678

4.  Aldehyde dehydrogenase activity plays no functional role in stem cell-like properties in anaplastic thyroid cancer cell lines.

Authors:  Mika Shimamura; Tomomi Kurashige; Norisato Mitsutake; Yuji Nagayama
Journal:  Endocrine       Date:  2016-12-31       Impact factor: 3.633

Review 5.  Thyroid cancer in 2010: a roadmap for targeted therapies.

Authors:  Francesca Carlomagno; Massimo Santoro
Journal:  Nat Rev Endocrinol       Date:  2011-02       Impact factor: 43.330

Review 6.  Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Authors:  Pamela Jo Harris; Keith C Bible
Journal:  Expert Opin Investig Drugs       Date:  2011-10       Impact factor: 6.206

Review 7.  Novel approaches in anaplastic thyroid cancer therapy.

Authors:  Kun-Tai Hsu; Xiao-Min Yu; Anjon W Audhya; Juan C Jaume; Ricardo V Lloyd; Shigeki Miyamoto; Tomas A Prolla; Herbert Chen
Journal:  Oncologist       Date:  2014-09-26

Review 8.  Stem cells and cancer stem-like cells in endocrine tissues.

Authors:  Ricardo V Lloyd; Heather Hardin; Celina Montemayor-Garcia; Fabio Rotondo; Luis V Syro; Eva Horvath; Kalman Kovacs
Journal:  Endocr Pathol       Date:  2013-03       Impact factor: 3.943

9.  Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.

Authors:  C Visciano; F Liotti; N Prevete; G Cali'; R Franco; F Collina; A de Paulis; G Marone; M Santoro; R M Melillo
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

10.  Cancer stem cells as a potential therapeutic target in thyroid carcinoma.

Authors:  Luisa Vicari; Cristina Colarossi; Dario Giuffrida; Ruggero De Maria; Lorenzo Memeo
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.